UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy

Annals of oncology, 2014-11, Vol.25 (11), p.2211-2217

2014

Volltextzugriff (PDF)

MAHOGANY: A PHASE 3 TRIAL OF ZANUBRUTINIB PLUS ANTI‐CD20 VERSUS LENALIDOMIDE PLUS RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR OR MARGINAL ZONE LYMPHOMA

Hematological oncology, 2023-06, Vol.41 (S2), p.168-170

2023

Volltextzugriff (PDF)

Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study

Annals of oncology, 2018-09, Vol.29 (9), p.1932-1938

2018

Volltextzugriff (PDF)

Unmet needs in the first-line treatment of follicular lymphoma

Annals of oncology, 2017-09, Vol.28 (9), p.2094-2106

2017

Volltextzugriff (PDF)

Metabolic tumor volume predicts outcome in patients with advanced stage follicular lymphoma from the RELEVANCE trial

Annals of oncology, 2024-01, Vol.35 (1), p.130-137

2024

Volltextzugriff (PDF)

IBRUTINIB PLUS BR OR R‐CHOP IN PREVIOUSLY TREATED PATIENTS WITH FOLLICULAR OR MARGINAL ZONE LYMPHOMA: THE PHASE 3 SELENE STUDY

Hematological oncology, 2023-06, Vol.41 (S2), p.872-874

2023

Volltextzugriff (PDF)

Role of the tumor microenvironment in mature B-cell lymphoid malignancies

Haematologica (Roma), 2016-05, Vol.101 (5), p.531-540

2016

Volltextzugriff (PDF)

Autologous stem cell transplantation for untreated transformed indolent B‐cell lymphoma in first remission: an international, multi‐centre propensity‐score‐matched study

British journal of haematology, 2020-12, Vol.191 (5), p.806-815

2020

Volltextzugriff (PDF)

A Phase II Investigator Initiated Study of Acalabrutinib, Lenalidomide and Rituximab (aR2) in Patients with Previously Untreated High Tumor Burden Follicular Lymphoma

Hematological oncology, 2023-06, Vol.41 (S2), p.383-383

2023

Volltextzugriff (PDF)

Patients with classical Hodgkin lymphoma experiencing disease progression after treatment with brentuximab vedotin have poor outcomes

Annals of oncology, 2016-07, Vol.27 (7), p.1317-1323

2016

Volltextzugriff (PDF)

Factors influencing outcome in advanced stage, low-grade follicular lymphoma treated at MD Anderson Cancer Center in the rituximab era

Annals of oncology, 2016-05, Vol.27 (5), p.895-901

2016

Volltextzugriff (PDF)

Brentuximab Vedotin‐Nivolumab alone and then with Rituximab‐Cyclophosphamide‐Doxorubicin‐Prednisone as Frontline Therapy of Primary Mediastinal Large B‐cell Lymphoma

Hematological oncology, 2023-06, Vol.41 (S2), p.167-168

2023

Volltextzugriff (PDF)

SMART STOP: A PHASE II CLINICAL TRIAL OF LENALIDOMIDE, TAFASITAMAB, RITUXIMAB, AND ACALABRUTINIB ALONE AND WITH RESPONSE ADAPTED CHEMOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED DLBCL

Hematological oncology, 2023-06, Vol.41 (S2), p.837-838

2023

Volltextzugriff (PDF)

P1182: REAL‐WORLD CHARACTERISTICS AND CLINICAL OUTCOMES IN RELAPSE/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA PATIENTS WHO RECEIVED CAR‐T THERAPY

HemaSphere, 2022-06, Vol.6 (Suppl), p.1068-1069

2022

Volltextzugriff (PDF)

OPEN‐LABEL PHASE 1/2 STUDY OF CC‐99282, A CEREBLON E3 LIGASE MODULATOR (CELMOD) AGENT ± RITUXIMAB, IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) NON‐HODGKIN LYMPHOMA (NHL)

Hematological oncology, 2023-06, Vol.41 (S2), p.134-136

2023

Volltextzugriff (PDF)

RADIOMICS REFLECTING BOTH TUMOR AND HOST FEATURES IMPROVES OUTCOME PREDICTION IN FOLLICULAR LYMPHOMA

Hematological oncology, 2023-06, Vol.41 (S2), p.94-95

2023

Volltextzugriff (PDF)

MOSUNETUZUMAB DEMONSTRATES DURABLE RESPONSES IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND ≥2 PRIOR THERAPIES: UPDATED ANALYSIS OF A PIVOTAL PHASE II STUDY

Hematological oncology, 2023-06, Vol.41 (S2), p.122-125

2023

Volltextzugriff (PDF)

LISOCABTAGENE MARALEUCEL (LISO‐CEL) VERSUS STANDARD OF CARE (SOC) AS SECOND‐LINE THERAPY IN LARGE B‐CELL LYMPHOMA (TRANSFORM STUDY): SUBGROUP ANALYSES BY PRIOR THERAPY RESPONSE

Hematological oncology, 2023-06, Vol.41 (S2), p.212-214

2023

Volltextzugriff (PDF)

Defining Primary Refractory Diffuse Large B‐cell Lymphoma (DLBCL) Based on Survival Outcomes

Hematological oncology, 2023-06, Vol.41 (S2), p.430-432

2023

Volltextzugriff (PDF)

ZUMA‐22: A PHASE 3, RANDOMIZED CONTROLLED STUDY OF AXICABTAGENE CILOLEUCEL (AXI‐CEL) VS STANDARD‐OF‐CARE THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA

Hematological oncology, 2023-06, Vol.41 (S2), p.853-855

2023

Volltextzugriff (PDF)

ACALABRUTINIB WITH RITUXIMAB AS FIRST‐LINE THERAPY FOR OLDER PATIENTS WITH MANTLE CELL LYMPHOMA—A PHASE II CLINICAL TRIAL

Hematological oncology, 2023-06, Vol.41 (S2), p.150-151

2023

Volltextzugriff (PDF)

IBRUTINIB‐RITUXIMAB AND VENETOCLAX (IRV) FOLLOWED BY RISK‐STRATIFIED R‐HYPERCVAD/MTX IN YOUNG PATIENTS WITH UNTREATED MANTLE CELL LYMPHOMA—PHASE‐II WINDOW‐2 TRIAL

Hematological oncology, 2023-06, Vol.41 (S2), p.152-153

2023

Volltextzugriff (PDF)

TRANSCEND FL: PHASE 2 STUDY RESULTS OF LISOCABTAGENE MARALEUCEL (LISO‐CEL) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL)

Hematological oncology, 2023-06, Vol.41 (S2), p.877-880

2023

Volltextzugriff (PDF)

BONE MARROW VOLUME IRRADIATED AND RISK OF CYTOPENIAS IN AGGRESSIVE B‐CELL LYMPHOMA PATIENTS BRIDGED WITH RADIATION THERAPY FOR CART CELL THERAPY

Hematological oncology, 2023-06, Vol.41 (S2), p.222-223

2023

Volltextzugriff (PDF)

A low lymphocyte‐to‐monocyte ratio (LMR) predicts PFS, POD24 and OS in previously untreated, high tumor burden follicular lymphoma (FL): an analysis from the RELEVANCE trial

Hematological oncology, 2023-06, Vol.41 (S2), p.290-291

2023

Volltextzugriff (PDF)

1 – 25 von 346

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(337)
Mit Volltextzugriff
(275)

Publikationsform

Sprache

Englisch
(346)

Erscheinungsjahr

n.n

Thema

Science & Technology
(103)
Life Sciences & Biomedicine
(102)
Humans
(89)
Lymphoma
(69)
Hematology
(66)
Oncology
(55)
Adult
(44)
Female
(42)
Middle Aged
(41)
Male
(38)
Aged
(37)
Rituximab
(30)
Treatment Outcome
(28)
Targeted Cancer Therapy
(22)
Monoclonal Antibodies
(21)
Patients
(21)
Immunotherapy
(20)
Retrospective Studies
(20)
Aged, 80 And Over
(19)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(19)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy

MAHOGANY: A PHASE 3 TRIAL OF ZANUBRUTINIB PLUS ANTI‐CD20 VERSUS LENALIDOMIDE PLUS RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR OR MARGINAL ZONE LYMPHOMA

Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study

Unmet needs in the first-line treatment of follicular lymphoma

Metabolic tumor volume predicts outcome in patients with advanced stage follicular lymphoma from the RELEVANCE trial

IBRUTINIB PLUS BR OR R‐CHOP IN PREVIOUSLY TREATED PATIENTS WITH FOLLICULAR OR MARGINAL ZONE LYMPHOMA: THE PHASE 3 SELENE STUDY

Role of the tumor microenvironment in mature B-cell lymphoid malignancies

Autologous stem cell transplantation for untreated transformed indolent B‐cell lymphoma in first remission: an international, multi‐centre propensity‐score‐matched study

A Phase II Investigator Initiated Study of Acalabrutinib, Lenalidomide and Rituximab (aR2) in Patients with Previously Untreated High Tumor Burden Follicular Lymphoma

Patients with classical Hodgkin lymphoma experiencing disease progression after treatment with brentuximab vedotin have poor outcomes

Factors influencing outcome in advanced stage, low-grade follicular lymphoma treated at MD Anderson Cancer Center in the rituximab era

Brentuximab Vedotin‐Nivolumab alone and then with Rituximab‐Cyclophosphamide‐Doxorubicin‐Prednisone as Frontline Therapy of Primary Mediastinal Large B‐cell Lymphoma

SMART STOP: A PHASE II CLINICAL TRIAL OF LENALIDOMIDE, TAFASITAMAB, RITUXIMAB, AND ACALABRUTINIB ALONE AND WITH RESPONSE ADAPTED CHEMOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED DLBCL

P1182: REAL‐WORLD CHARACTERISTICS AND CLINICAL OUTCOMES IN RELAPSE/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA PATIENTS WHO RECEIVED CAR‐T THERAPY

OPEN‐LABEL PHASE 1/2 STUDY OF CC‐99282, A CEREBLON E3 LIGASE MODULATOR (CELMOD) AGENT ± RITUXIMAB, IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) NON‐HODGKIN LYMPHOMA (NHL)

RADIOMICS REFLECTING BOTH TUMOR AND HOST FEATURES IMPROVES OUTCOME PREDICTION IN FOLLICULAR LYMPHOMA

MOSUNETUZUMAB DEMONSTRATES DURABLE RESPONSES IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND ≥2 PRIOR THERAPIES: UPDATED ANALYSIS OF A PIVOTAL PHASE II STUDY

LISOCABTAGENE MARALEUCEL (LISO‐CEL) VERSUS STANDARD OF CARE (SOC) AS SECOND‐LINE THERAPY IN LARGE B‐CELL LYMPHOMA (TRANSFORM STUDY): SUBGROUP ANALYSES BY PRIOR THERAPY RESPONSE

Defining Primary Refractory Diffuse Large B‐cell Lymphoma (DLBCL) Based on Survival Outcomes

ZUMA‐22: A PHASE 3, RANDOMIZED CONTROLLED STUDY OF AXICABTAGENE CILOLEUCEL (AXI‐CEL) VS STANDARD‐OF‐CARE THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA

ACALABRUTINIB WITH RITUXIMAB AS FIRST‐LINE THERAPY FOR OLDER PATIENTS WITH MANTLE CELL LYMPHOMA—A PHASE II CLINICAL TRIAL

IBRUTINIB‐RITUXIMAB AND VENETOCLAX (IRV) FOLLOWED BY RISK‐STRATIFIED R‐HYPERCVAD/MTX IN YOUNG PATIENTS WITH UNTREATED MANTLE CELL LYMPHOMA—PHASE‐II WINDOW‐2 TRIAL

TRANSCEND FL: PHASE 2 STUDY RESULTS OF LISOCABTAGENE MARALEUCEL (LISO‐CEL) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL)

BONE MARROW VOLUME IRRADIATED AND RISK OF CYTOPENIAS IN AGGRESSIVE B‐CELL LYMPHOMA PATIENTS BRIDGED WITH RADIATION THERAPY FOR CART CELL THERAPY

A low lymphocyte‐to‐monocyte ratio (LMR) predicts PFS, POD24 and OS in previously untreated, high tumor burden follicular lymphoma (FL): an analysis from the RELEVANCE trial

Suchergebnisse filtern